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Is there a role for continuous renal replacement therapies
in patients with liver and renal failure?
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Is there a role for continuous renal replacement therapies in have pre-existing renal glomerular and/or tubular dis-
patients with liver and renal failure? Continuous renal replace- ease related to their primary liver disease.
ment therapy (CRRT) has now been in use for more than a
decade in the management of patients with combined renal
and hepatic failure. CRRT remains the treatment of choice in
RENAL REPLACEMENT MODALITYthis group of critically ill patients because of improved cardio-
vascular and intracranial stability when compared with conven- When continuous forms of hemofiltration and dialysis
tional intermittent hemofiltration and/or dialysis and effective
were first introduced into the treatment of patients withsolute clearances when compared with forms of peritoneal
combined hepatic and renal failure, spontaneous circuitsdialysis. Over the last decade, the technique has evolved with
the introduction of pumped CRRT circuits, using machines were used [5]. Subsequently, these have generally been
that can accurately regulate fluid balance, and the commercial replaced by pumped continuous renal replacement ther-
introduction of bicarbonate-based or “lactate-free” substitu-
apy (CRRT) circuits so that the CRRT circuit is notion fluids and/or dialysates. Whether continuous dialysis or
longer dependent on the mean arterial pressure, whichhemofiltration is the mode of treatment choice remains unan-
swered, with greater amino acid and ammonia losses during is usually reduced despite vasoconstrictor requirement
dialysis, whereas hemofiltration leads to increased middle mol- [6]. Compared with peritoneal dialysis, CRRT provides
ecule and cytokine removal when compared with dialysis, the
improved clearances and has a more predictable fluidlatter mainly caused by membrane adsorption. Whether the
balance [7]. Although the relative rate of solute clearanceimproved cardiovascular stability observed during these tech-
niques is due to the removal of inflammatory mediators or is is greater during conventional intermittent hemodialysis,
related to cooling as a consequence of the technique remains the absolute daily clearance is greater for CRRT, pro-
to be determined.
vided the circuit functions throughout the day [7]. More
recently, slow overnight dialysis has been introduced
using conventional dialysis equipment, but with reducedPatients with hepatocellular failure, whether acute or
blood flows and dialysate flows, and can achieve similarchronic, characteristically have generalized changes in
clearances to CRRT.circulatory dynamics, which are characterized by an in-
creased cardiac output with reduced systemic vascular
Cardiovascular stabilityresistance, with evidence of tissue hypoxia [1]. This
One of the advantages reported by the pioneers ofshunting of blood through the tissues, with resultant tis-
sue hypoxia, is greater in those patients with acute liver CRRT was improved cardiovascular stability and the
failure and can be assessed using an oxygen flux test [2]. ability to treat patients who otherwise would have been
Thus, these patients are prone to develop acute renal considered too unstable for conventional hemodialysis.
failure either because of acute tubular necrosis, usually However, over the past decade, there have been many
secondary to renal ischemic injury [3], or hepatorenal technological advances in hemodialysis for patients with
failure, when the normal autoregulatory renal compensa- acute renal failure, including the introduction of daily
tory mechanisms to preserve renal perfusion have been treatments with the use of biocompatible membranes,
reset [4]. In addition, patients may develop acute renal priming the dialyzer and lines with albumin, high sodium
failure secondary to nephrotoxic drugs and may also dialysate concentrations, cooling the dialysate and the
ability to continuously monitor plasma volume during
treatment. Despite these measures, patients with cardio-Key words: renal and hepatic failure, critical care, fluid balance, hepato-
cellular failure, acute renal failure. vascular instability, typified by those with acute hepatic
failure, remain a group who can be problematic to dialyze 1999 by the International Society of Nephrology
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cently, it has been shown that cerebral ischemia is the
more common form of brain injury [11] and that cerebral
hypoxia then leads to the development of cerebral edema
[1]. Thus, it is important in those patients who have lost
cerebral autoregulation that both cerebral hypoxia and
hypotensive episodes are avoided.
Typically, intermittent hemodialysis results in an in-
crease in intracranial pressure, even in stable chronic
dialysis patients. Within the first hour of dialysis, there
is a significant detectable fall in the serum osmolality,
and this may lead to the movement of plasma water into
the extracellular and intracellular spaces because of the
concentration gradient. In addition, hypotensive epi-
sodes or a net reduction in the effective circulating vol-
Fig. 1. Continuous blood volume measurement during conventional ume may result in cerebral hypoxia and the production
intermittent hemodialysis, set at an ultrafiltration rate of 100 ml/hr,
of so-called idiogenic osmoles, thus increasing the con-with a low-flux polysulfon dialyzer, blood pump speed 200 ml/min,
centration gradient and the backflow of water into thedialysate sodium 145 mmol/liter, and cooled to temperature of 358C.
These changes in blood volume occurred despite boluses of colloid brain tissue [12]. In patients with acute liver failure,
infusions and increasing pressor support with norepinephrine.
surges of intracranial pressure during intermittent hemo-
filtration and/or dialysis were typically detected both
within the first hour and then toward the end of the
treatment session. This suggests that changes in cerebral(Fig. 1). Typically these patients develop hypotension
within the first few minutes of connection to the dialysis perfusion and cerebral hypoxia were the most important
factors in determining cerebral stability [10]. Peritonealcircuit [8] because of a reduction in systemic vascular
resistance and the effective circulating blood volume [9]. dialysis has been reported to not adversely affect the
intracranial pressure when used to manage acute renalPlasma nitric oxide concentrations are increased in
patients with liver failure, and this may be due to defec- failure in neurosurgical patients. However, in liver fail-
ure patients, fluid balance may be problematical, as ultra-tive endotoxin extraction by the liver. At the start of
dialysis, patients with acute liver failure have a greater filtration depends on the peritoneal blood supply. Many
of these patients have abnormal portal blood flow, andincrease in plasma nitric oxide than those with chronic
liver disease and a much larger increase when compared vasoconstrictive agents such as norepinephrine reduce
gastrointestinal blood flow. In addition, sudden changeswith stable chronic hemodialysis patients [9]. Patients
with liver failure treated by CRRT show greater cardio- in vascular tone associated with peritoneal drainage (Fig.
2) may provoke cerebral hypoxia and lead to brain death.vascular stability when compared with intermittent he-
mofiltration or hemodialysis when initially connected to The introduction of CRRT provided a technique to
treat acute renal failure in patients with cardiovascularthe circuit and during treatment [8]. Stability was greatest
with spontaneous CRRT, followed by pumped CRRT. instability and cerebral edema. This allowed the survival
of patients with raised intracranial pressure with acuteThis suggests that blood pump speed and the initial inter-
action between the patient’s blood and the extracorpo- liver failure, who otherwise would have died [13]. Al-
though the most likely explanation for this increasedreal circuit are important factors in determining this va-
sodilatory hypotension. As those patients with the most intracranial stability was improved cardiovascular stabil-
ity, compared with intermittent hemodialysis and/or fil-labile cardiovascular responses and the most severe liver
failure have almost undetectable plasma complement tration, the rate of change of plasma osmolality was much
smaller [10]. In addition, it was anecdotally noted thatproteins, it is unlikely that dialyzer–complement interac-
tions play a significant role [10]. some patients who had raised intracranial pressure prior
to starting CRRT developed increased intracranial pres-
Intracranial pressure sure following the discontinuation of CRRT while wait-
ing transfer to theater for orthotopic liver transplanta-Although intracranial hypertension has been reported
in patients with chronic liver failure, it is typically found tion, suggesting that CRRT may improve cerebral
stability by removing a cardiodepressant or a vascularin those with fulminant hepatic failure [1]. The shorter
the time interval between the start of symptoms and the endothelial vasodilatory factor.
onset of encephalopathy, then the greater risk of cerebral
Electrolyte balanceedema. Originally, many patients with fulminant hepatic
failure were reported as dying from intracranial hyper- When orthotopic liver transplantation was in its in-
fancy, patient survival was limited, and thus, many pa-tension with coning and cerebellar herniation. More re-
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Fig. 2. Patient with renal failure and raised intracranial
pressure treated by automated peritoneal dialysis. At
each cycle exchange, there was a marked reduction in
the mean arterial blood pressure, despite resuscitation
attempts with colloid and increasing pressor doses, re-
sulting in a fall in cerebral perfusion pressure and even-
tual death from brain ischemia.
tients referred with end-stage liver failure were severely
hyponatremic. Several centers reported encephalopathy
and even patient death caused by central pontine my-
elinosis caused by too rapid of a correction of the serum
sodium as a consequence of transplantation [14]. We and
others have successfully used CRRT to correct severe
hyponatremia (serum sodium ,120 mmol/liter) prior to
liver transplantation [15]. The rate of rise of sodium is
determined by both the rate of replacement fluid/dialy-
sate flow and the sodium composition. At this controlled
rate of increase, the serum sodium concentration can be
normalized without the risk of pontine myelinosis.
Fig. 3. Microalbumin losses in the ultrafiltrate during isovolemic veno-Similarly, CRRT has proved effective in controlling
venous hemofiltration, set at an ultrafiltration rate of 1000 ml/hr, using
postorthotopic liver transplantation electrolyte imbal- two similar surface area membranes, differing in their respective surface
zeta (z) potentials (polyacrylonitrile very negative z potential). Symbolsances, typically hypernatremia, secondary to the sodium
are: (d) polyamide; (m) polyacrylonitrile.load from colloid infusions and sodium citrate in blood
products, and hypercalcemia from repeated calcium ad-
ministration.
in a patient with deteriorating hepatic function, and other
Middle molecule clearance
bridges to hepatic transplantation are required [20].
Hemofiltration and hemodialysis essentially remove
Membrane bioincompatibilitywater soluble solutes. Although there have been reports
of CRRT removing copper in cases of Wilson’s disease There has been great interest in cytokine removal dur-
[5], amino acids [16], and ammonia in fulminant hepatic ing CRRT. Patients with liver failure, possibly as a conse-
failure [17, 18], the majority of patients died when treated quence of defective endotoxin removal, are known to
by hemofiltration alone or in combination with other have increased circulating levels of proinflammatory cy-
extracorporeal techniques, such as plasma exchange [18]. tokines, particularly tumor necrosis factor-a. During
The amount of solutes removed depends on the tech- CRRT, cytokine removal is mainly by membrane adsorp-
nique used, being greater for hemodiafiltration than he- tion and is therefore greater during hemofiltration than
mofiltration alone [16], and on both the plasma concen- hemodialysis [21]. Membrane adsorption depends on the
tration [17] and the rate of dialysate flow/ultrafiltration negative membrane surface charge, known as the zeta
rate [18]. Thus, although CRRT is very effective in main- (z) potential, the membrane surface area, and the blood
taining circulatory, acid-base, and electrolyte balance in flow rate. Membranes differ in their z potential, and
the anhepatic patient awaiting supraurgent transplanta- this affects protein permeability and adsorption (Fig. 3).
Thus, as expected, adsorption is maximal within the firsttion [19], alone it is inadequate to maintain homeostasis
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hour of treatment, whereas convective losses are rela- added in the venous return limb of the CRRT circuit,
have been developed.tively constant during treatment [21]. This suggests that
there would be an advantage of regularly changing the Compared with standard lactate-based solutions, we
found that during the first day of CRRT, the averageCRRT hemofilter membrane to increase such adsorption
losses. fall in arterial hydrogen ion concentration was 12 nmol/
liter greater, and the total amount of anionic buffer ad-Studies have suggested that both the initial cardiovas-
cular and intracranial stability in patients with acute liver ministered was 225 mmol less when bicarbonate was
used [28].failure when starting hemofiltration may be affected by
membrane bioincompatibility [8, 22]. This implies that Thus, the commercial development of bicarbonate or
buffer-free–based fluids should supersede lactate and ac-some of the cardiovascular instability observed in these
patients is due to increased endothelial dysfunction sec- etate-based fluids.
ondary to increased proinflammatory cytokines.
SUMMARYAnticoagulation
The development of CRRT in the management ofMost patients with fulminant hepatic failure are at
acute renal failure in patients with both acute and chronicincreased risk of hemorrhage, with markedly abnormal
liver failure has been a major advance over the last de-throboelastographs, caused by a combination of clotting
cade. It allowed the treatment of patients who werefactor deficiencies, thrombocytopenia, and low-grade
cardiovascularly too unstable to tolerate conventionalfibrinolysis with or without intravascular coagulation.
hemodialysis and provided excellent solute removalThus, many of these patients can be managed with anti-
when compared with peritoneal dialysis. Althoughcoagulation-free CRRT circuits, especially if predilution
CRRT is not a substitute for a failing liver, it can befluid replacement is used [23]. However, some patients
used to correct electrolyte imbalance prior to trans-frequently clot their circuits. This is not thought to be
plantation and to help maintain anhepatic patients thatdue to activation of the traditional extrinsic coagulation
are awaiting urgent transplantation. Intraoperatively,cascade [23, 24] but due to increased activity of the intrin-
CRRT is conventionally used during liver transplanta-sic pathway, secondary to the release of tissue factor
tion for those with acute liver failure and/or renal dys-[24]. Endotoxemia activates endothelial cells and primes
function prior to transplantation.macrophages and other inflammatory cells to increase
the release of tissue factor, thus increasing thrombin Reprint requests to Andrew Davenport, M.D., Center for Nephrology,
Royal Free Hospital, Pond Street, London NW3 2QG, England, Unitedgeneration by the intrinsic pathway.
Kingdom.Anticoagulation with heparin may not be that effective
E-mail: davenport@rfhsm.ac.uk
in these patients because of reduced concentrations of
antithrombin III and heparin cofactor II [23]. Similarly,
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